Lazcluze

Product Overview

About Lazcluze

Lazcluze is a type of cancer medicine called a tyrosine kinase inhibitor.

What it is used for

Not available in this source.

How it is used

The medicine can only be obtained with a prescription. Treatment with Lazcluze should be started by a doctor who is experienced in using cancer medicines. Before starting treatment, patients must be tested to confirm that the tumour cells have certain changes to the EGFR gene. Lazcluze is available as tablets to be taken by mouth once a day. Treatment should continue until the disease gets worse or unacceptable side effects occur. At the initiation of treatment, patients should be given anticoagulants (substances that prevent the blood from clotting) to reduce risks of venous thromboembolic events (VTE, problems due to the formation of blood clots in veins).

How it works

The active substance in Lazcluze, lazertinib, blocks the activity of EGFR, a protein which normally controls the growth and division of cells. In lung cancer cells, EGFR is often overactive, causing uncontrolled growth of cancer cells. By blocking EGFR, lazertinib helps to reduce the growth and spread of the cancer. Lazertinib primarily targets the mutated EGFR and has less effect on normal EGFR, therefore minimising undesirable effects caused by blocking normal EGFR.

Active substance: lazertinib

Source: EMA EPAR